On Mother’s Day in 2019, I walked into the ICU on the ninth floor of University of California, San Francisco’s Parnassus campus for the last time. It had been a month since my mom, Holly, was discharged from the hospital there after having a bilateral lung transplant. Although I…
Football and science seem to be disparate fields of play at first glance, but the nonprofit Uplifting Athletes is finding common ground by leveraging the popularity of college gridiron games to fund research for rare diseases. Its nearly two dozen chapters — representing college football teams across the nation…
A Phase 2 clinical trial evaluating Endeavor BioMedicines’ experimental oral therapy taladegib (ENV-101) in people with idiopathic pulmonary fibrosis (IPF), has dosed its first patient. The trial (NCT04968574) is enrolling adults, ages 40 and older, with mild-to-moderate IPF at one Australian site, with at least three more…
Photo courtesy of Tracey Harms Day 23 of 30 This is Joan Ciccarelli’s story: My name is Joan Ciccarelli. I am 83 years old and have lived with IPF for at least 12 years. I have tried everything possible to help myself and my well-being. These days, I…
Photo courtesy of Rand O’Brien Day 22 of 30 This is Rand O’Brien’s story: It started when I began feeling short of breath when I reached my third-floor office. I thought it might be my heart since two years prior, I’d had two stents put in. But after my…
For Pulmonary Fibrosis Awareness Month, held each September, the biopharmaceutical company Boehringer Ingelheim Canada has created the Life with PF campaign to help patients better understand the stages of this progressive disease and to empower them to obtain much-needed care. The initiative, which is aimed at…
Photo courtesy of Kevin Olson Day 21 of 30 This is Kevin Olson’s story: I joined the Greater Kansas City Pulmonary Fibrosis Support Group, making several new friends who would influence my life. Unfortunately, we would lose some of them to this dreadful disease. I am honoring some…
Cudetaxestat (BLD-0409), an investigational treatment for idiopathic pulmonary fibrosis (IPF) being developed by Blade Therapeutics, does not interact with the approved IPF treatment Ofev (nintedanib), according to research done in rats. “We believe that these are important data that help inform our step-wise approach to advance the clinical…
Photo courtesy of Eileen Koster Day 20 of 30 This is Eileen Koster’s story: My IPF journey started in 2015. Asthma, allergies, and chronic cough made my job difficult as a flight attendant, so I made an appointment to see a pulmonologist. A year later, he recommended treatment…
Adding co-trimoxazole or doxycycline — two broad-spectrum antibiotics — to standard care does not significantly slow lung function decline or prolong survival in people with idiopathic pulmonary fibrosis (IPF), a review study has found. This approach was instead associated with a higher risk of side effects, specifically gastrointestinal issues.
Get regular updates to your inbox.
